- Home
- TBPH vs HUYA Comparison
TBPH vs HUYA Comparison
Compare TBPH & HUYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- HUYA
- Stock Information
- Founded
- TBPH 2013
- HUYA 2014
- Country
- TBPH United States
- HUYA China
- Employees
- TBPH N/A
- HUYA N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- HUYA Computer Software: Programming Data Processing
- Sector
- TBPH Health Care
- HUYA Technology
- Exchange
- TBPH Nasdaq
- HUYA Nasdaq
- Market Cap
- TBPH 699.0M
- HUYA 713.8M
- IPO Year
- TBPH N/A
- HUYA 2018
- Fundamental
- Price
- TBPH $14.26
- HUYA $2.90
- Analyst Decision
- TBPH Strong Buy
- HUYA Buy
- Analyst Count
- TBPH 4
- HUYA 3
- Target Price
- TBPH $23.00
- HUYA $4.57
- AVG Volume (30 Days)
- TBPH 301.7K
- HUYA 1.1M
- Earning Date
- TBPH 11-11-2025
- HUYA 11-11-2025
- Dividend Yield
- TBPH N/A
- HUYA 86.01%
- EPS Growth
- TBPH N/A
- HUYA N/A
- EPS
- TBPH 0.26
- HUYA N/A
- Revenue
- TBPH $77,205,000.00
- HUYA $852,782,043.00
- Revenue This Year
- TBPH $79.82
- HUYA $8.16
- Revenue Next Year
- TBPH N/A
- HUYA $5.11
- P/E Ratio
- TBPH $54.87
- HUYA N/A
- Revenue Growth
- TBPH 24.49
- HUYA N/A
- 52 Week Low
- TBPH $7.90
- HUYA $2.21
- 52 Week High
- TBPH $15.15
- HUYA $4.59
- Technical
- Relative Strength Index (RSI)
- TBPH 54.96
- HUYA 29.20
- Support Level
- TBPH $13.50
- HUYA $3.03
- Resistance Level
- TBPH $14.59
- HUYA $3.40
- Average True Range (ATR)
- TBPH 0.50
- HUYA 0.09
- MACD
- TBPH -0.09
- HUYA -0.04
- Stochastic Oscillator
- TBPH 46.31
- HUYA 8.56
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About HUYA HUYA Inc. American depositary shares each representing one ordinary share
Huya, officially became independent in 2016 and headquartered in Guangzhou, operates live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. As of 2024, Huya was a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power.